Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
NEW YORK, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ
3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond
06:18am, Saturday, 18'th Jan 2025
Dividend cuts can be devastating to an income-focused investor. You lose a portion of your passive income, and a dividend stock's price tends to fall significantly leading up to and after a payout red
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ
NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning pos
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
08:00am, Friday, 17'th Jan 2025
In fact, Johnson & Johnson is one of the companies that is part of the exclusive dividend kings. The company has been increasing its dividend for 62 consecutive years, and the company's rock-solid bal
Johnson & Johnson: Q4 Earnings May Not Prompt Sustained Directional Moves
11:29am, Thursday, 16'th Jan 2025
Johnson & Johnson has underperformed its lerge-cap healthcare peers and the S&P 500, with an -8% decline over the past year. Even though JNJ has displayed an improvingtrack record of beating consensus
Insights Into Johnson & Johnson (JNJ) Q4: Wall Street Projections for Key Metrics
10:20am, Thursday, 16'th Jan 2025
Beyond analysts' top -and-bottom-line estimates for Johnson & Johnson (JNJ), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for th
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Investors to Connect
10:00am, Thursday, 16'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ
Dogs of the Dow: Can These 3 Laggards Turn a Corner in 2025?
08:50am, Thursday, 16'th Jan 2025
The Dogs of the Dow strategy doesn't always work. Often, it can lead investors to a laggard poised to lag behind for yet another year.
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
08:46am, Thursday, 16'th Jan 2025
JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer patients.
The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems
07:30am, Thursday, 16'th Jan 2025
In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable di
Blood-Based Multi-Cancer Early Detection (MCED) Technologies Poised to Offer Lucrative Opportunities Blood-Based Multi-Cancer Early Detection (MCED) Technologies Poised to Offer Lucrative Opportunitie
Buy 3 'Safer' Dividend Kings Of 25 From 53 For January
12:39pm, Wednesday, 15'th Jan 2025
“A Dividend King [is] a stock with 50 or more consecutive years of dividend increases.”—suredividend.com. 53 Divided Kings, screened as of January 10, 2025, represented all eleven Morningstar Se
JNJ ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Johnson & Johnson
10:30am, Wednesday, 15'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible viol
